GMI-1271

Research use only, not for human use.

A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM.

A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM; weakly inhibits L-selectin (IC50=2.9 uM) and >10 uM for P-selectin; not only mobilizes AML cells out of protective niches but also blocks NF-kB activation and prevents this E-selectin-mediated chemoresistance, thereby enhancing the therapeutic effects of standard chemotherapy; also overcomes MM metastasis and chemoresistance.Blood Cancer Phase 2 Clinical.

——

——

GMI1271 | Uproleselan sodium

Cytoskeleton/Cell Adhesion Molecules

Selectin

Selectin

Cancer

Blood cancer

1914993-95-5

1326.508

C60H108N3NaO27

>98% (HPLC)

——

O=C([O-])[C@@H](O[C@@H]1[C@@H](NC(C)=O)[C@H](O[C@H]2[C@H](O[C@H]3[C@H]([C@@H]([C@@H]([C@H](CO)O3)O)O)O)[C@@H](CC)C[C@@H](C(NCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)C2)O[C@H](CO)[C@@H]1O)CC4CCCCC4.[Na+]

4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxaoctatriacontanamide, N-[2-[[[(1R,3R,4R,5S)-3-[[2-(acetylamino)-3-O-[(1S)-1-carboxy-2-cyclohexylethyl]-2-deoxy-b-D-galactopyranosyl]oxy]-4-[(6-deoxy-a-L-galactopyranosyl)oxy]-5-ethylcyclohexyl]carbonyl]amino]ethyl

(-20℃)

With Ice Pack

≥ 2 years